REFILE-AstraZeneca fights to regain cancer market prominence

June 4, 2014 12:15 AM

16 0

CHICAGO, June 3 (Reuters) - AstraZeneca Plc, in the headlines for spurning buyout offers from Pfizer Inc, aims to regain prominence in oncology with compelling trial results and a splashy exhibit booth at the world's largest meeting of cancer doctors.

The company is seen as No. 4 in a race to develop the first drug in a new class that fights cancer by unleashing the body's immune system, behind rivals Roche, Merck & Co and Bristol-Myers Squibb.

Also read: Buyer Beware: Hundreds of Bitcoin Wannabes Show Hallmarks of Fraud

Read more

To category page